Natural Killer (NK) cells are innate immune effectors: they can exert natural cytotoxicity and secrete cytokines and chemokines in the absence of sensitization (1). NK cells also mediate antibody-dependent cellular cytotoxicity (ADCC) via Fcγ RIIL (CD16). Via multiple receptors, NK cells can select (with Natural Killer Receptors: NKRs) and lyse (with NKG2D, and Natural Cytotoxicity Receptors: NCRs) a variety of target cells, as reviewed in Ref. 2. Unlike NKRs, NCRs are strictly restricted to NK cells. To date, and beside many existing coreceptors, 3 NCRs have been identified: NKp46, NKp44 and NKp30. Their common features are (1):

- a direct involvement in target cell recognition and killing;
- the delivery of activating signals (3) by association with ITAM-containing molecules (KARAP / DAP12, or CD3ζ, or FcgRα/γ);
- they belong to the Immunoglobulin superfamily;
- unknown ligands;
- their surface density varies in different individuals and also in the NK cells isolated from a given individual;
- there is a direct correlation between their surface density and the ability of NK cells to kill various target cells;
- their collective blocking with monoclonal antibodies strongly inhibits NK-mediated cytolyis.

The discovery of NKp46 resulted from the selection of monoclonal antibodies that triggered NK-mediated target cell lysis (4). BAB281 was selected on these criteria, and helped identify NKp46, a 46 kDa trans-membrane glycoprotein, strictly expressed by all NK cells, including the infrequent CD3-CD56+ T cells. These data indicate that NKp46 may be a "all NK / only NK" marker (4). A weak expression of NKp46 has been described on MZ93 (11) and NK-92 (12) cell lines. The monoclonal antibody BAB281 was first studied on human NK cells (4) and exhibits the following properties:

- BAB281 reacts with all and only mature NK cells, also in Macaques (13);
- BAB281 binding to NKp46 induces a strong increase of cytolytic activity in redirected killing assays, also in Macaque (13);
- this triggering was also observed on CD16+ NK cells, which did not respond to anti-CD16 antibodies;
- the NKp46-induced triggering was abolished by the simultaneous cross-linking of KIRs and CD94 / NKG2A (4);
- BAB281 binding to NKp46 induces mobilization of intracellular Calcium;
- BAB281 masking of NKp46 induces a strong inhibition of NK-mediated natural cytotoxicity against HLA-Class I-negative or autologous cells covered with an anti-HLA-Class I antibody (7).

The molecular cloning of NKp46 (5), and biochemical studies (6), revealed that NKp46 is associated with the ITAM-containing CD3ζ, although the NKp46 expression on the cell surface does not require that of CD3ζ. The surface density of NKp46 is linked to the cytolytic activity of NK cells (7). NKp46, as NKp30, is involved in the interaction of NK cells with autologous antigen-presenting cells (8). Recent findings illustrate the role of NKp46 in NK cytotoxic mechanisms in response to intracellular infection: microbial ligands for NKp46 have been identified: hemagglutinin of the influenza virus, and hemagglutinin of the Sendai virus (9). In addition, it was recently reported that freshly isolated NK cells from healthy subjects can lyse Mycobacterium tuberculosis-infected monocytes, and that the lysis is abolished by an anti-NKp46 antiserum. In tuberculosis patients, the NK cell lytic activity was reduced (10).

Beyond its role in triggering natural cytotoxicity, the cellular distribution of NKp46 is noteworthy: on freshly isolated PBMCs, NKp46 is strictly restricted to CD3-CD56+ cells, including CD56dim/CD16+; in addition, NKp46 is not expressed by the rare CD16+CD56- T cells. These data indicate that NKp46 may be a "all NK / only NK" marker (4). A weak expression of NKp46 has been described on MZ93 (11) and NK-92 (12) cell lines. The monoclonal antibody BAB281 was first studied on human NK cells (4) and exhibits the following properties:

- BAB281 reacts with all and only mature NK cells, also in Macaques (13);
- BAB281 binding to NKp46 induces a strong increase of cytolytic activity in redirected killing assays, also in Macaque (13);
- this triggering was also observed on CD16+ NK cells, which did not respond to anti-CD16 antibodies;
- the NKp46-induced triggering was abolished by the simultaneous cross-linking of KIRs and CD94 / NKG2A (4);
- BAB281 binding to NKp46 induces mobilization of intracellular Calcium;
- BAB281 masking of NKp46 induces a strong inhibition of NK-mediated natural cytotoxicity against HLA-Class I-negative or autologous cells covered with an anti-HLA-Class I antibody (7).

REAGENT
IOTest NKp46-PE Conjugated Antibodies
PN IM3711 – 50 tests – 20 µL / test – Clone BAB281

SPECIFICITY
Natural Killer (NK) cells are innate immune effectors: they can exert natural cytotoxicity and secrete cytokines and chemokines in the absence of sensitization (1). NK cells also mediate antibody-dependent cellular cytotoxicity (ADCC) via Fcγ RIIL (CD16). Via multiple receptors, NK cells can select (with Natural Killer Receptors: NKRs) and lyse (with NKG2D, and Natural Cytotoxicity Receptors: NCRs) a variety of target cells, as reviewed in Ref. 2. Unlike NKRs, NCRs are strictly restricted to NK cells. To date, and beside many existing coreceptors, 3 NCRs have been identified: NKp46, NKp44 and NKp30. Their common features are (1):

- a direct involvement in target cell recognition and killing;
- the delivery of activating signals (3) by association with ITAM-containing molecules (KARAP / DAP12, or CD3ζ, or FcgRα/γ);
- they belong to the Immunoglobulin superfamily;
- unknown ligands;
- their surface density varies in different individuals and also in the NK cells isolated from a given individual;
- there is a direct correlation between their surface density and the ability of NK cells to kill various target cells;
- their collective blocking with monoclonal antibodies strongly inhibits NK-mediated cytolyis.

The discovery of NKp46 resulted from the selection of monoclonal antibodies that triggered NK-mediated target cell lysis (4). BAB281 was selected on these criteria, and helped identify NKp46, a 46 kDa trans-membrane glycoprotein, strictly expressed by all NK cells, including the infrequent CD3-CD56+ T cells. These data indicate that NKp46 may be a "all NK / only NK" marker (4). A weak expression of NKp46 has been described on MZ93 (11) and NK-92 (12) cell lines. The monoclonal antibody BAB281 was first studied on human NK cells (4) and exhibits the following properties:

- BAB281 reacts with all and only mature NK cells, also in Macaques (13);
- BAB281 binding to NKp46 induces a strong increase of cytolytic activity in redirected killing assays, also in Macaque (13);
- this triggering was also observed on CD16+ NK cells, which did not respond to anti-CD16 antibodies;
- the NKp46-induced triggering was abolished by the simultaneous cross-linking of KIRs and CD94 / NKG2A (4);
- BAB281 binding to NKp46 induces mobilization of intracellular Calcium;
- BAB281 masking of NKp46 induces a strong inhibition of NK-mediated natural cytotoxicity against HLA-Class I-negative or autologous cells covered with an anti-HLA-Class I antibody (7).

REAGENT
IOTest NKp46-PE Conjugated Antibodies
PN IM3711 – 50 tests – 20 µL / test – Clone BAB281

Isotype IgG1, mouse

Immunogen Human NK clone (SE192)

Source Ascites fluid

Purification Ion exchange or affinity chromatography

Conjugation R-phycocerythin (PE) is conjugated at 0.5 – 1.5 moles of PE per mole of Ig.

Excitation wavelength: 488 nm

Maximum emission wavelength: 575 nm

Main emission color: Orange-red

Buffer 2 mg/mL bovine serum albumin in phosphate-buffered saline containing 0.1% sodium azide.

APPLICATION

STATEMENT OF WARNINGS
For Research Use Only. Not For Use In Diagnostic Procedures.

1) ”Fix-and-lyse” mixture: by freshly mixing 1 mL of VersaLyse (PN IM3648) with 25 µL of undiluted IOTest 3 Fixative Solution (PN IM3515), Prepare a sufficient amount of the “fix-and-lyse” mixture for the total number of samples.

2) Fixing buffer: by mixing 6.25 µL of undiluted IOTest 3 Fixative Solution (PN IM3515) in 0.5 mL PBS. Prepare a sufficient amount of the fixing buffer for the total number of samples.

NOTE: Unlike what is stated on the package insert of the the IOTest 3 Fixative Solution (PN IM3515), the present procedure does not use this fixative solution as a 10X concentrated solution.

PROCEDURE
Preparation of working solutions (quantity for 1 tube):

1) "Fix-and-lyse" mixture: by freshly mixing 1 mL of VersaLyse (PN IM3648) with 25 µL of undiluted IOTest 3 Fixative Solution (PN IM3515), Prepare a sufficient amount of the “fix-and-lyse” mixture for the total number of samples.

2) Fixing buffer: by mixing 6.25 µL of undiluted IOTest 3 Fixative Solution (PN IM3515) in 0.5 mL PBS. Prepare a sufficient amount of the fixing buffer for the total number of samples.

NOTE: Unlike what is stated on the package insert of the the IOTest 3 Fixative Solution (PN IM3515), the present procedure does not use this fixative solution as a 10X concentrated solution.

Procedure:

1. Label tubes for analysis.

2. Pipet into each tube 20µL of the monoclonal antibody (mAb) or mAb mixture.

3. Add 100 µL of whole blood.

4. Incubate at room temperature (18 – 25°C) for 20 minutes. Protect from light.

5. Add 1 mL of the "fix-and-lyse" mixture to each tube and vortex immediately for one second after each addition.

6. Centrifuge the tubes at 150 x g for at least 10 minutes. Let tubes sit, protected from light.

7. Centrifuge the tubes at 150 x g for 5 minutes and discard the supernatant by aspiration.

8. Add 3 mL of PBS.

9. Centrifuge the tubes at 150 x g for 5 minutes and discard the supernatant by aspiration.

10. Resuspend the pellets by addition of 0.5 mL of fixing buffer.
which represents the NK cells.

EXAMPLE DATA

The graphs below illustrate the strategy used to study NK receptors on NK cells. They were obtained on normal whole blood samples labeled with CD3-FITC / CD56-PC5 and NKp46-PE, and lysed according to the procedure described above.

Isotypic Control (PN IM0670) labeling is shown underneath in light. Acquisition is with a COULTER® EPICS® XL™ flow cytometer. Analysis is with the Beckman Coulter Expo32™ software.

SELECTED RESEARCH REFERENCES

3. [5701] Tomassello, E., Blyé, M., Vély, F., Vivier, E., "Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells", 2000, Seminars in Immunology, 12, 139-147.
9. [5604] IOTest® NKp46-PE Conjugated Antibodies

PRODUCT AVAILABILITY

IOTest® NKp46-PE Conjugated Antibodies PN IM3711 – 50 tests – 20 µL / test

PE is licensed under patent 4,520,110

For additional information in the USA, call 800-526-7964.

Outside the USA, contact your local Beckman Coulter representative.

TRADEMARKS

IOTest® is a registered trademark of Immunotech S.A.

Manufactured by:
Immunotech, a Beckman Coulter Company
130, avenue de Lattre de Tassigny, B.P. 177
13276 Marseille Cedex 9, France

www.beckmancoulter.com